Haeberlein SB, Gheuens S, Chen T, et al. Aducanumab 36-month data from PRIME: a randomized, double-blind, placebocontrolled phase 1b study in patients with prodromal or mild Alzheimer’s disease. AAN 2018, S2.004.
Modificeerbare overlappende risicofactoren voor beroerte, dementie en depressie
jul 2025 | Dementie, Neuro-vasculair